What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to announce Amgen's unaudited financial results for the second quarter and the first six months of 2008. It also provides detailed explanations and reconciliations of the non-GAAP financial measures the company is reporting alongside its GAAP results.

Why is Amgen reporting non-GAAP financial measures?

Amgen reports non-GAAP financial measures because it believes they provide useful supplementary information to investors. These measures exclude certain expenses and charges that the company deems non-recurring or not indicative of ongoing operational performance, such as restructuring costs, acquisition-related expenses, and stock option expensing, thereby facilitating better period-over-period comparisons.

What specific types of charges are being excluded in the non-GAAP figures?

The non-GAAP figures exclude a variety of items, including the impact of expensing stock options, restructuring charges related to manufacturing operations and research facilities, merger-related expenses from various acquisitions (like Alantos, Avidia, Abgenix), legal accruals, amortization of acquired intangible assets, and specific tax effects related to these adjustments.

Are these non-GAAP measures a replacement for GAAP results?

No, Amgen explicitly states that its non-GAAP financial measures are presented in addition to, not as a substitute for, or superior to, measures of financial performance prepared in accordance with U.S. Generally Accepted Accounting Principles (GAAP). Investors should always consider both GAAP and non-GAAP figures for a comprehensive financial understanding.

AMGN 8-K: Earnings & Results

Summary

Amgen Inc. (AMGN) filed this 8-K report on July 28, 2008, to announce its unaudited financial results for the second quarter and first half of 2008. The report primarily focuses on providing non-GAAP financial measures, which the company believes offer a more insightful view for investors by excluding certain charges and expenses. These adjustments include the impact of expensing stock options, restructuring charges related to manufacturing operations, expenses from acquisitions (Alantos, Avidia, Abgenix, Tularik, Immunex), legal accruals, and amortization of acquired intangible assets. The company presents these non-GAAP measures as supplementary to GAAP results to facilitate better period-over-period comparisons, particularly in light of significant integration and restructuring activities. Investors should note that the company's presentation of non-GAAP figures is intended to provide a clearer picture of ongoing operational performance by stripping out non-recurring or non-cash items. This includes costs associated with strategic initiatives like acquisitions and operational restructuring, as well as the accounting impact of stock option expensing. While these adjusted figures can be useful, it is crucial for investors to also review the company's reported GAAP results to understand the full financial picture and the impact of all reported items.

Key Highlights

1Amgen reported its unaudited financial results for the three and six months ended June 30, 2008.
2The company provided non-GAAP financial measures, adjusting for items like stock option expensing, restructuring charges, acquisition-related costs, legal accruals, and amortization of intangible assets.
3Adjustments in 2008 included costs from the 2008 Restructuring Amounts (manufacturing rationalization, R&D facility moderation), Alantos Acquisition expenses, and Legal Accruals.
4In 2007, adjustments included 2007 Restructuring Amounts, merger-related expenses (Abgenix, Tularik), a Manufacturing Charge, and Convertible Notes Expense.
5The report details adjustments to cost of sales, R&D, SG&A, and diluted shares for calculating adjusted earnings per share, aiming to provide a clearer operational view.
6Amgen emphasized that these non-GAAP measures are supplementary to GAAP and are used internally for budgeting and financial planning.
7The filing includes a press release dated July 28, 2008, as Exhibit 99.1, which contains the detailed financial results and reconciliations.

AMGEN INC 8-K Report, Financial Results (Jul 28, 2008)

Summary

Key Highlights

Frequently Asked Questions